Institutional Clinical and Translational Science Award

机构临床和转化科学奖

• 批准号: 10227357
• 负责人: GARRET A FITZGERALD
• 金额: $ 16.19万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-07-01 至 2021-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10227357
• 关键词: Academia; Adult; Area; Biological Models; Biotechnology; Cell model; Center for Translational Science Activities; Chemicals; Childhood; Clinical; Clinical Research; Clinical Sciences; Clinical and Translational Science Awards; Congresses; Development; Devices; Discipline; Disease; Dose; Drug Approval; Drug Exposure; Educational process of instructing; Evolution; Faculty; First Independent Research Support and Transition Awards; Fostering; Functional disorder; Funding; Geography; Growth; Home environment; Human; Incentives; Institutes; Institution; Longevity; Measures; Mission; Modeling; Pediatric Hospitals; Pennsylvania; Pharmaceutical Preparations; Pharmacologic Substance; Phenotype; Philadelphia; Physiological; Physiology; Population; Private Sector; Process; Research; Research Personnel; Resources; Safety; Schools; Science; Signal Transduction; The Wistar Institute; Therapeutic; Time; Transcend; Translational Research; Translations; United States National Institutes of Health; Universities; Vision; clinical investigation; drug action; interest; medical schools; novel; novel therapeutics; pre-clinical; precision medicine; programs; recruit; response; translational medicine

Contact PD/PI: FITZGERALD, GARRET A OVERALL ABSTRACT/SUMMARY The Institute for Translational Medicine and Therapeutics is the academic home for the CTSA in Penn. For the past decade the specific aims of ITMAT have been and remain (i) to increase the number of investigators capable of pursuing their research between proof of concept in cells and model systems and (ii) elucidation of the mechanisms of human physiology, disease or drug action through intense phenotyping in small numbers of people. The two priorities of our CTSA are to foster the field of translational therapeutics and to bridge the pediatric to adult divide across the entire spectrum of clinical and translational science. This section describes how these priorities have influenced the growth of this CTSA Hub and outlines our plans for the coming funding period. Project Summary/Abstract Page 103 Contact PD/PI: FITZGERALD, GARRET A OVERALL NARRATIVE The Institute for Translational Medicine and Therapeutics is the academic home for the CTSA in Penn. For the past decade the specific aims of ITMAT have been and remain (i) to increase the number of investigators capable of pursuing their research between proof of concept in cells and model systems and (ii) elucidation of the mechanisms of human physiology, disease or drug action through intense phenotyping in small numbers of people.

联系人 PD/PI：FITZGERALD、GARRET A 全面的 摘要/总结 转化医学和治疗研究所是 CTSA 的学术所在地 佩恩。在过去十年中，ITMAT 的具体目标始终是 (i) 提高 能够在细胞概念验证之间进行研究的研究人员数量 和模型系统以及（ii）阐明人类生理学、疾病或 通过在少数人群中进行强烈的表型分析来确定药物作用。我们的两个优先事项 CTSA 旨在培育转化治疗领域并架起儿科与成人之间的桥梁 整个临床和转化科学领域的划分。本节描述 这些优先事项如何影响 CTSA 中心的发展并概述我们的计划 即将到来的资助期。 项目总结/摘要第 103 页 联系人 PD/PI：FITZGERALD、GARRET A 全面的 叙述 转化医学和治疗研究所是 CTSA 的学术所在地 佩恩。在过去十年中，ITMAT 的具体目标始终是 (i) 提高 能够在细胞概念验证之间进行研究的研究人员数量 和模型系统以及（ii）阐明人类生理学、疾病或 通过在少数人群中进行强烈的表型分析来确定药物作用。